Emergent BioSolutions (CGT)
Baltimore, MD
Hybrid — also manufactures internal programs
4 confirmed programs
· 1 sponsors
· Last scored 2026-10-29
66.1
Signal Score
○ FDA Inspections
✓ Clinical Trials (4)
✓ SEC Filings (23)
○ Press
○ EMA GMP
○ MHRA GMP
✓ HC GMP (3)
Quick Facts: Emergent BioSolutions (CGT)
- Signal Score
- 66.1/100 (as of 2026-10-29)
- Quality Compliance
- Assessment pending
- Headquarters
- Baltimore, MD
- Modalities
- AAV, Adenoviral
- Active Programs
- 4 confirmed from ClinicalTrials.gov across 1 sponsors
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
- Scored By
- CDMO Signal — independent CDMO intelligence platform
About Emergent BioSolutions (CGT)
Government contractor with viral vector capabilities.
Signal Score & Pillar Breakdown
Quality Compliance
—
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
Health Canada Non-compliant1
Most Recent HC OutcomeNon-compliant · 2022-02-07
HC Attribution3 company-level
Source: Health Canada Drug and Health Product Inspections Database. Ratings shown in Health Canada's own vocabulary; not equivalent to FDA classifications. Company-level records are attributed by the regulator's published establishment name, not by a verified site identifier. Contains information licensed under the Open Government Licence – Canada.
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations
55.0
4 active programs across 1 sponsors
Modalities: Adenoviral, AAV
2 programs in advanced phases (Phase 2/3)
Source: ClinicalTrials.gov
4 active programs across 1 sponsors · Modalities: Adenoviral, AAV · 2 programs in advanced phases (Phase 2/3)
Programs
4
Sponsors1
ModalitiesAAV, Adenoviral
4 active programs across 1 sponsors
Modalities: Adenoviral, AAV
2 programs in advanced phases (Phase 2/3)
Source: ClinicalTrials.gov facility matching
Source: ClinicalTrials.gov · Retrieved Nov 21, 2026
Financial Stability
83.0
Publicly traded — financial transparency
Source: company profile (public/private status, parent company)
23 SEC filings with industry mentions on record (shown, not scored)
SEC Filings23 with industry mentions (not scored)
Publicly traded — financial transparency
Capacity
63.0
2 manufacturing sites
Sites: Baltimore, MD, Bayview, MD
Source: company profiles (manufacturing sites, modality breadth)
2 manufacturing sites
2 manufacturing sites
EMA Non-Compliance Statements 1
BE/NC/2022/01 — Emergent Manufacturing Operations Baltimore LLC, United States
Issued: 2022-04-01
Issued: 2022-04-01
Source: EMA EudraGMDP · Retrieved Nov 21, 2026
Clinical Activity 4 studies
NCT03160339
A Study to Assess the Safety, Pharmacodynamics, and Immunogenicity of PXVX0047
PHASE1
Terminated
NCT01979406
A Phase 1 Ascending Dose Study to Assess the Safety and Immunogenicity of...
PHASE1
Completed
NCT00893516
CD4 in Combination With CHOP in Treating Non-cutaneous Peripheral TCell Lymphoma
PHASE2
Terminated
NCT00877656
HuMax-CD4 in Non-Cutaneous T-Cell Lymphoma
PHASE2/PHASE3
Completed
Source: ClinicalTrials.gov · Retrieved Nov 21, 2026
Hiring Activity Beta
From public job postings on the parent company's careers board, as of Nov 20, 2026. Job postings are signals, not statements by the company; each one below links to the original. How we collect this
No open roles were listed at this business's sites on Nov 20, 2026.
Coverage: read from the parent company's careers board and kept only postings at this business's sites (Emergent CDMO sites in the profile (Bayview/Camden, Baltimore)). Roles outside those sites are left out, and some of this unit's roles may be missed.
Function groups come mainly from job titles (about 84% match a hand check), and modality words from titles only, so both are approximate.
Source:
careers.emergentbiosolutions.com
· Checked Nov 20, 2026 · Tracking since Oct 26, 2026
Financial Intelligence
"Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers: On October 16, 2026, Emergent BioSolutions Inc. (the “"
"Item 7.01 Regulation FD Disclosure: On September 14, 2026, Joseph C. Papa, president and chief executive officer of Emergent BioSolutions Inc., will present at the H.C. Wainwright 28th Annual Global Investment Conference. Mr. Papa will present the slides furnished as Exhibit 99.1 to this Current Report on Form 8-K, which are incorporated herein by reference."
"Item 8.01 Other Events: On August 18, 2026, Emergent BioSolutions Inc. (“Emergent”) received a contract modification (“Modification No. 21”) of the BARDA AV7909 Contract (as defined below) from the Office of the Assistant Secretary for Preparedness and Response to procure additional doses of CYFENDUS™ (Anthrax Vaccine Adsorbed, Adjuvanted) (previously known as “AV7909”) valued at $24 million."
"The Company's solutions include a product portfolio, a product development portfolio, and a contract development and manufacturing (“CDMO”) services portfolio."
"As such, the key components of the business structure include the following
four
product and service categories: Anthrax - Medical Countermeasures (“MCM”) products, Naloxone Commercial products, Smallpox - MCM products and Emergent Bioservices (CDMO) (“Bioservices”)."
"The Company’s solutions include a product portfolio, a product development portfolio, and a contract development and manufacturing services (“CDMO”) portfolio."
"Item 2.02 Results of Operations and Financial Condition: On August 5, 2026, Emergent BioSolutions Inc. (the "Company") issued a press release (the "Press Release") announcing its financial and operating results for the quarter ended June 30, 2026. A copy of the Press Release is furnished as Exhibit 99.1 to this Current Report on Form 8-K (this "Form 8-K") and is incorporated herein by reference."
"Item 2.05 Costs Associated with Exit or Disposal Activities: On August 5, 2026, the Company announced an organizational restructuring plan (the “Restructuring Plan”) intended to strengthen its long-term financial position in response to changes in its business. These strategic actions will lead to a reduction of the Company’s current workforce by approximately 93 employees across all areas of the Company and the elimination of approximately 21 positions that are currently vacant, as well as the "
"Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers: In connection with the actions described above, on August 5, 2026 the Company also announced that it will eliminate the role of Chief Medical Officer, Head of Research and Development. As such, Simon Lowry, the Company’s Chief Medical Officer, Head of Research and Development will be leaving the Company effective August 19, 2026. The Company"
"Item 1.01 Entry into a Material Definitive Agreement: On June 26, 2026 , Emergent BioSolutions Inc. (the “Company,” including its wholly-owned subsidiaries, “Emergent”), through its wholly-owned subsidiary, Emergent Product Development Gaithersburg Inc., received a contract modification from the Office of the Assistant Secretary for Preparedness and Response (“ASPR”), an agency of the U.S. Department of Health and Human Services (“Modification No. 15”), exercising Option Year 7 for Emergent to s"
"Item 7.01 Regulation FD Disclosure: On June 29, 2026, the Company issued a press release announcing Modification No. 15. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein."
"The Company's solutions include a product portfolio, a product development portfolio, and a contract development and manufacturing (“CDMO”) services portfolio."
"As such, the key components of the business structure include the following
four
product and service categories: Anthrax - Medical Countermeasures (“MCM”) products, Naloxone Commercial products, Smallpox - MCM products and Emergent Bioservices (CDMO) (“Bioservices”)."
"The Company’s solutions include a product portfolio, a product development portfolio, and a contract development and manufacturing services (“CDMO”) portfolio."
"Our solutions include a product portfolio, a product development portfolio, and a contract development and manufacturing (“CDMO”) services portfolio."
"Commercial products, consisting of NARCAN
®
Nasal Spray and KLOXXADO
®
, Anthrax – Medical Countermeasures (“MCM”) Products, Smallpox - MCM products, and Emergent Bioservices (CDMO) (“Bioservices”)."
"Bioservices
We also compete for bioservices with several biopharmaceutical product R&D organizations, contract manufacturers of biopharmaceutical products (CDMOs), other bioservices organizations, and university research laboratories."
"The Company's solutions include a product portfolio, a product development portfolio, and a contract development and manufacturing (“CDMO”) services portfolio."
"As such, the key components of the business structure include the following
four
product and service categories: Anthrax - Medical Countermeasures (“MCM”) products, Naloxone commercial products, Smallpox - MCM products and Emergent Bioservices (CDMO) (“Bioservices”)."
"August 2023 Organizational Restructuring Plan
In August 2023, the Company initiated the August 2023 Plan, which was intended to strengthen its core business and financial position by reducing investment in and de-emphasizing focus on its CDMO services business for future growth."
"The Company's solutions include a product portfolio, a product development portfolio, and a contract development and manufacturing (“CDMO”) services portfolio."
"As such, the key components of the business structure include the following
four
product and service categories: Anthrax - Medical Countermeasures (“MCM”) products, Naloxone commercial products, Smallpox - MCM products and Emergent Bioservices (CDMO) (“Bioservices”)."
"August 2023 Organizational Restructuring Plan
In August 2023, the Company initiated the August 2023 Plan, which was intended to strengthen its core business and financial position by reducing investment in and de-emphasizing focus on its CDMO services business for future growth."
"The Company's solutions include a product portfolio, a product development portfolio, and a contract development and manufacturing (“CDMO”) services portfolio."
"As such, the key components of the business structure include the following
four
product and service categories: Anthrax - Medical Countermeasures (“MCM”) Products, NARCAN
®
commercial product, Smallpox - MCM products and Emergent Bioservices (CDMO) (“Bioservices”)."
"August 2023 Organizational Restructuring Plan
In August 2023, the Company initiated the August 2023 Plan, which was intended to strengthen its core business and financial position by reducing investment in and de-emphasizing focus on its CDMO services business for future growth."
"Our solutions include a product portfolio, a product development portfolio, and a contract development and manufacturing (“CDMO”) services portfolio."
"NARCAN
®
commercial product, Anthrax - Medical Countermeasures (“MCM”) Products, Smallpox - MCM products and Emergent Bioservices (CDMO) (“Bioservices”
)."
"The Company's solutions include a product portfolio, a product development portfolio, and a contract development and manufacturing services (“CDMO”) portfolio."
"The Company's solutions include a product portfolio, a product development portfolio, and a contract development and manufacturing (“CDMO”) services portfolio."
"As such, the key components of the business structure include the following
four
product and service categories: NARCAN
®
commercial product, Anthrax - Medical Countermeasures (“MCM”) Products, Smallpox - MCM products and Emergent Bioservices (CDMO) (“Bioservices”)."
"Services Segment:
Bioservices - CDMO
The Company’s services revenue consists of distinct but interrelated bioservices: drug substance manufacturing; drug product manufacturing (also referred to as “fill/finish” services) and packaging; development services including technology transfer, process and analytical development services; and, when necessary, suite reservation obligations."
"The Company's solutions include a product portfolio, a product development portfolio, and a contract development and manufacturing ("CDMO") services portfolio."
"As such, the key components of the business structure include the following
four
product and service categories: NARCAN
®
commercial product, Anthrax - Medical Countermeasures (“MCM") Products, Smallpox - MCM products and Emergent Bioservices (CDMO) ("Bioservices")."
"Services Segment:
Bioservices - CDMO
The Company’s services revenue consists of distinct but interrelated bioservices: drug substance manufacturing; drug product manufacturing (also referred to as "fill/finish" services) and packaging; development services including technology transfer, process and analytical development services; and, when necessary, suite reservation obligations."
"The Company's solutions include a product portfolio, a product development portfolio, and a contract development and manufacturing ("CDMO") services portfolio."
"As such, the key components of the business structure include the following
four
product and service categories: NARCAN
®
commercial product, Anthrax - Medical Countermeasures (“MCM") Products, Smallpox - MCM products and Emergent Bioservices (CDMO) ("Bioservices")."
"Services Segment:
Bioservices - CDMO
The Company’s services revenue consists of distinct but interrelated bioservices: drug substance manufacturing; drug product manufacturing (also referred to as "fill/finish" services) and packaging; development services including technology transfer, process and analytical development services; and, when necessary, suite reservation obligations."
Source: SEC EDGAR · Retrieved Nov 21, 2026
Frequently Asked Questions About Emergent BioSolutions (CGT)
How many clinical programs is Emergent BioSolutions (CGT) linked to?
Emergent BioSolutions (CGT) is associated with 4 clinical trials in CDMO Signal's ClinicalTrials.gov-sourced data.
What is Emergent BioSolutions (CGT)'s CDMO Signal Score?
Emergent BioSolutions (CGT) has a Signal Score of 66/100, based on quality, operations, financial stability, and capacity data.
Evaluating Emergent BioSolutions (CGT) for a manufacturing program?
Use the free AI matchmaker to compare Emergent BioSolutions (CGT) against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
Similar CDMOs
Rose BioSolutions
Rockville, MD · Memphis, TN · Keele, United Kingdom
Signal Score: 64.0
AAV, Lentiviral, Adenoviral, Plasmid, Cell Therapy, CAR-T
SK pharmteco
Dublin, Ireland. Rancho Cordova, CA. King of Prussia, PA. Houston, TX. Korea. France.
Signal Score: 79.5
Viral Vectors, AAV, Lentiviral, Adenoviral, HPAPIs, Small Molecules, Peptides, BioCatalysis, Chromatography, Cell Therapy
Exothera
Jumet, BE
Signal Score: 78.1
AAV, Adenoviral, Lentiviral
Advent Bioservices
London, United Kingdom
Signal Score: 78.1
AAV, Lentiviral, Adenoviral
Thermo Fisher Scientific
Plainville, MA · Alachua, FL · Cambridge, MA
Signal Score: 77.6
AAV, Lentiviral, Plasmid DNA, Adenoviral, Plasmid, Small Molecule API, Oral Solid Dose, Sterile Fill-Finish
Compare Emergent BioSolutions (CGT) with another CDMO
Side-by-side scoring, FDA inspection history, EMA/MHRA GMP coverage, and clinical-program footprint.